NDAINTRAVENOUSPOWDER
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
KYPROLIS (carfilzomib) by Dr. Reddy's Laboratories is proteasome inhibitors [moa]. First approved in 2012.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYPROLIS (carfilzomib) is a second-generation proteasome inhibitor administered intravenously as a powder formulation. It is indicated for multiple myeloma and works by selectively inhibiting the 20S proteasome, inducing apoptosis in malignant plasma cells. The drug has been on the market since 2012 and remains in peak commercial performance.
$0.014BPart D
Peak7.2 years to LOEThe product is at peak lifecycle with 1,357 Medicare Part D claims in 2023, indicating stable commercial performance with established market presence; team size likely reflects mature commercial operations.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Started Feb 2026
70 enrolled
Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Started Jan 2026
915 enrolled
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Started Jun 2025
440 enrolled
Multiple Myeloma
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Started Mar 2025
64 enrolled
Plasma Cell Myeloma Refractory
Worked on KYPROLIS at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.